Sung Hye Kong1, Junsun Ryu2,3, Min Joo Kim1, Sun Wook Cho1, Young Shin Song1, Ka Hee Yi4, Do Joon Park1,5, Yul Hwangbo3,6, You Jin Lee3,6, Kyu Eun Lee7, Su-Jin Kim7, Woo-Jin Jeong8, Eun-Jae Chung9, Jeong Hun Hah9, June Young Choi10, Chang Hwan Ryu2,3, Yuh-Seog Jung2,3, Jae Hoon Moon11, Eun Kyung Lee3,6, Young Joo Park1. 1. 1Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea. 2. 2Department of Otorhinolaryngology, National Cancer Center, Goyang, Republic of Korea. 3. 3Center for Thyroid Cancer, National Cancer Center, Goyang, Republic of Korea. 4. 4Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea. 5. 5Korea National Institute of Health, Cheongju, Republic of Korea. 6. 6Department of Internal Medicine, National Cancer Center, Goyang, Republic of Korea. 7. 7Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea. 8. 8Department of Otorhinolaryngology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 9. 9Department of Otorhinolaryngology, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea. 10. 10Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 11. 11Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Abstract
Background: In this ongoing multicenter prospective cohort study on active surveillance (AS) in low-risk papillary thyroid microcarcinoma (PTMC), we aimed to compare the quality of life (QoL) of participants based on their choice of treatment, that is, AS or immediate surgery (OP). Methods: QoL of 203 participants who chose AS and 192 participants who underwent OP was evaluated using a thyroid-specific QoL questionnaire at diagnosis and during follow-up (median 8 months). Results: The mean ages of the participants in the AS and OP groups were 47.3 ± 11.7 and 45.6 ± 10.5 years (p = 0.138), respectively, and the mean tumor sizes were 5.7 ± 1.6 and 6.5 ± 2.1 mm (p = 0.065), respectively. At baseline, significantly better psychological health (7.1 ± 1.3 vs. 6.8 ± 1.6, p = 0.023) and overall health (6.8 ± 1.2 vs. 6.5 ± 1.3, p = 0.018) were observed in the AS group than in the OP group. During follow-up, significantly better physical (7.9 ± 1.1 vs. 7.4 ± 1.2, p < 0.001), psychological (7.4 ± 1.3 vs. 6.9 ± 1.6, p = 0.004), and overall health (6.9 ± 1.0 vs. 6.5 ± 1.1, p = 0.002) were observed in the AS group than in the OP group, whereas spiritual health was comparable between the two groups. Compared with the AS group, the OP group experienced more fatigue, changes in voice and appearance, less satisfaction, and low fear of recurrence. The self-assessed financial burden was similar at baseline and follow-up in both groups. Conclusion: The QoL of PTMC patients is different according to the type of treatment. Better psychological health at baseline and physical and psychological health at follow-up were observed in the AS group than in the OP group. However, studies with longer follow-up periods are needed.
Background: In this ongoing multicenter prospective cohort study on active surveillance (AS) in low-risk papillary thyroid microcarcinoma (PTMC), we aimed to compare the quality of life (QoL) of participants based on their choice of treatment, that is, AS or immediate surgery (OP). Methods: QoL of 203 participants who chose AS and 192 participants who underwent OP was evaluated using a thyroid-specific QoL questionnaire at diagnosis and during follow-up (median 8 months). Results: The mean ages of the participants in the AS and OP groups were 47.3 ± 11.7 and 45.6 ± 10.5 years (p = 0.138), respectively, and the mean tumor sizes were 5.7 ± 1.6 and 6.5 ± 2.1 mm (p = 0.065), respectively. At baseline, significantly better psychological health (7.1 ± 1.3 vs. 6.8 ± 1.6, p = 0.023) and overall health (6.8 ± 1.2 vs. 6.5 ± 1.3, p = 0.018) were observed in the AS group than in the OP group. During follow-up, significantly better physical (7.9 ± 1.1 vs. 7.4 ± 1.2, p < 0.001), psychological (7.4 ± 1.3 vs. 6.9 ± 1.6, p = 0.004), and overall health (6.9 ± 1.0 vs. 6.5 ± 1.1, p = 0.002) were observed in the AS group than in the OP group, whereas spiritual health was comparable between the two groups. Compared with the AS group, the OP group experienced more fatigue, changes in voice and appearance, less satisfaction, and low fear of recurrence. The self-assessed financial burden was similar at baseline and follow-up in both groups. Conclusion: The QoL of PTMC patients is different according to the type of treatment. Better psychological health at baseline and physical and psychological health at follow-up were observed in the AS group than in the OP group. However, studies with longer follow-up periods are needed.
Entities:
Keywords:
active surveillance; papillary thyroid microcarcinoma; physical health; psychological health; quality of life
Authors: Susan C Pitt; Nan Yang; Megan C Saucke; Nicholas Marka; Bret Hanlon; Kristin L Long; Alexandria D McDow; J P Brito; Benjamin R Roman Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 5.958
Authors: Anna M Sawka; Sangeet Ghai; Tom Yoannidis; Lorne Rotstein; Patrick J Gullane; Ralph W Gilbert; Jesse D Pasternak; Dale H Brown; Antoine Eskander; John R de Almeida; Jonathan C Irish; Kevin Higgins; Danny J Enepekides; Eric Monteiro; Avik Banerjee; Manish Shah; Everton Gooden; Afshan Zahedi; Mark Korman; Shereen Ezzat; Jennifer M Jones; Valeria E Rac; George Tomlinson; Aleksandra Stanimirovic; Amiram Gafni; Nancy N Baxter; David P Goldstein Journal: Thyroid Date: 2020-04-08 Impact factor: 6.568
Authors: Min Ji Jeon; Yea Eun Kang; Jae Hoon Moon; Dong Jun Lim; Chang Yoon Lee; Yong Sang Lee; Sun Wook Kim; Min-Hee Kim; Bo Hyun Kim; Ho-Cheol Kang; Minho Shong; Sun Wook Cho; Won Bae Kim Journal: Endocrinol Metab (Seoul) Date: 2021-03-23
Authors: Susan C Pitt; Megan C Saucke; Elizabeth M Wendt; David F Schneider; Jason Orne; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel Journal: Thyroid Date: 2020-11-04 Impact factor: 6.568